Insights
Insights From Our Experts
Articles
One Team, One Voice: The Impact of Centralized Medical Content Development
Featured Study – One Team, One Voice The Impact of Centralized Medical Content Development Presented at MAPS 2025. Objective: A survey was conducted to better understand Medical Affairs (MA) professionals’ strategies for medical content development, utilizing…
Maximizing Medical Affairs and MSL Impact: How Choosing a Strategic Launch Partner Propels Success
Medical Science Liaisons (MSLs) serve as the bridge between pharmaceutical companies, healthcare professionals, and the scientific community. Their impact reverberates across the entire healthcare ecosystem as they are essential for fostering scientific dialogue, driving evidence-based medicine,…
Uncovering the Drivers of Satisfaction for Patient Services
As the needs of patients and healthcare providers evolve, it is essential to continuously adapt support services to meet these changing demands. Dive into our latest article to discover strategies for improving patient and provider experiences…
Unlocking Pharma Success: Mike Ryan’s Pre-Conference Talk at Reuters Pharma 2025
Mike Ryan, General Manager, Europe, at EVERSANA, connected in a conversation with PharmaShots before Reuters Pharma 2025 in Barcelona, which ran 9-11 April 2025. Mike’s discussion focused on the history of EVERSANA and how the company…
Unlock the Power of Indirect Treatment Comparisons (ITC) with Industry Experts
Are you gearing up for product launches and health technology assessment (HTA) submissions? Look no further! EVERSANA is proud to announce an exclusive course at the ISPOR Education Center, led by renowned experts Chris Cameron from…
CASE STUDY: Transforming Clinical Trials with EVERSANA
Modernizing Clinical Trials to Accelerate Access Clinical trials are essential for bringing life-changing therapies to market, yet traditional models often present significant barriers for both participants and trial sites. A leading pharmaceutical manufacturer partnered with EVERSANA…
Beyond Clinical Trials: Real-World Evidence Illuminates the Value of First-Line CDK4/6i in Metastatic Breast Cancer
While randomized controlled trials (RCTs) have been instrumental in establishing new standards of care, a comprehensive understanding of treatment effectiveness requires insights from real-world evidence (RWE). This is particularly true in the evolving landscape of hormone…
Escaping the Chronic Microcap Trap: How Launching Alone Is the Only Option for Growth
As C-suite leaders in pharma wrestle with the pros and cons of launching alone, licensing or partnering with another company to launch their product, one factor they must consider is the impact their decision will have…
Case Study: Increasing Product Adoption Rate through EVERSANA’s Digital Hub Portal
Problem: Our client launched a new product in the U.S. market, but initial adoption rates were disappointingly low. Physicians, who were eager to incorporate this innovative product into their practice, hesitated to prescribe from the complexity…
Evaluating Talazoparib Plus Enzalutamide Against Standard of Care Therapies in Metastatic Castration-Resistant Prostate Cancer: A Matching-Adjusted Indirect Comparison
Posted by
Imtiaz Samjoo , Anja Haltner, MSc , Samantha Craigie , Sarah Walsh on March 27, 20253/27/25
Metastatic castration-resistant prostate cancer (mCRPC) is an incurable condition associated with poor prognosis and reduced quality of life. Historically, treatment options were limited, and despite recent advancements, the five-year survival rate for metastatic prostate cancer remains…